ライフサイエンスコーパス: prednisone

1 ophosphamide, vincristine, procarbazine, and prednisone).

2 controlled with adalimumab, tacrolimus, and prednisone.

3 stirsen and 512 were allocated docetaxel and prednisone.

4 lophosphamide, doxorubicin, vincristine, and prednisone.

5 herapy that included either dexamethasone or prednisone.

6 ared with historical controls on maintenance prednisone.

7 months of starting abiraterone acetate plus prednisone.

8 suggest sirolimus may rival standard of care prednisone.

9 of patients in 2000-2004 received melphalan-prednisone.

10 lophosphamide, doxorubicin, vincristine, and prednisone.

11 after oral paracetamol or a short course of prednisone.

12 4.1%-75.5%) vs 73% (90% CI, 63.8%-82.2%) for prednisone.

13 rly subgroups and among pairs receiving oral prednisone.

14 r D75 intravenously every 3 weeks plus daily prednisone.

15 y), or avacopan (30 mg, twice daily) without prednisone.

16 graft failure in the absence of maintenance prednisone.

17 imilar overall initial treatment efficacy as prednisone.

18 mycophenolic antimetabolite, and 70% were on prednisone.

19 for >=2 years on mycophenolate mofetil plus prednisone.

20 ared with patients receiving 0 to < 10 mg of prednisone.

21 mes in patients who received 0 to < 10 mg of prednisone.

22 olone 1 gm daily for 1 week followed by oral prednisone 1 mg/kg/d, tapered based on clinical and radi

23 g/m(2) intravenously every 21 days plus oral prednisone 10 mg daily) with or without custirsen (640 m

24 ents received growth factor support and oral prednisone 10 mg daily.

25 (2) on day 1 of each cycle intravenously and prednisone 100 mg once daily on days 1 to 5 of each cycl

26 bicin 50 mg/m(2) on day 1 intravenously, and prednisone 100 mg once daily on days 1-5 of each 21-day

27 ned, allowing us to reduce the daily dose of prednisone (15.9 +/- 13.6 mg/day vs 3.1 +/- 2.3 mg/day;

28 copan (30 mg, twice daily) plus reduced-dose prednisone (20 mg daily), or avacopan (30 mg, twice dail

29 Fifty severe asthmatics received prednisone 40 mg/d for 2 weeks and maintenance therapy w

30 [1.4 mg/m(2), up to 2 mg] all on day 1, and prednisone [40 mg/m(2)] daily for 5 days), administered

31 lower average requirement for alternate-day prednisone (44 mg vs. 60 mg, P<0.001).

32 one acetate (1000 mg) once daily orally plus prednisone (5 mg) once daily orally and ADT (abiraterone

33 e acetate, 1000 mg, once daily by mouth with prednisone, 5 mg, by mouth twice daily.

34 biraterone acetate, 1000 mg, once daily with prednisone, 5 mg, twice daily was administered to all pa

35 5, VP16 100 mg/m(2) D2, BCNU 100 mg/m(2) D3, prednisone 60 mg/kg/d D1-D5) followed by two cycles of R

36 on days 1 through 4 of each cycle), and oral prednisone (60 mg/m(2) once daily on days 1 through 4 of

37 was significantly higher for sirolimus than prednisone (66.7% vs 31.7%; P < .001).

38 total cohort (dexamethasone, 90.3 +/- 0.7%; prednisone, 90.5 +/- 0.7%).

39 vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) versus cyclophosphamide, doxorubicin,

40 G APML3 (single arm of ATRA + idarubicin +/- prednisone), ALLG APML4 (single arm of ATRA + idarubicin

41 over a 3-year period than those who received prednisone alone (6.15 vs. 8.99, P<0.001); patients in t

42 dnisone discontinuation was 35.8 months with prednisone alone compared with 29.4-29.7 months in the c

43 roup (n=501) compared with the docetaxel and prednisone alone group (n=499) were neutropenia (grade 3

44 completed the 60-month assessment, 24 in the prednisone alone group and 26 in the prednisone plus thy

45 en Sept 1, 2009, and Aug 26, 2015 (33 in the prednisone alone group and 35 in the prednisone plus thy

46 roup and 24 (5%) deaths in the docetaxel and prednisone alone group.

47 48 mg [29]; p=0.0002) than did those in the prednisone alone group.

48 omy combined with prednisone was superior to prednisone alone in improving clinical status as measure

49 139 patients via a computer-based system to prednisone alone or in combination with either ciclospor

50 red with patients treated with docetaxel and prednisone alone.

51 , and custirsen combination or docetaxel and prednisone alone.

52 and 181 (36%) of 499 receiving docetaxel and prednisone alone.

53 orin or methotrexate was more effective than prednisone alone.

54 -thymomatous myasthenia gravis compared with prednisone alone.

55 1:1) to either thymectomy plus prednisone or prednisone alone.

56 lophosphamide, doxorubicin, vincristine, and prednisone and 6 cyclophosphamide, doxorubicin, vincrist

57 comes and safety of abiraterone acetate plus prednisone and ADT from the final analysis of the LATITU

58 A 5-day course of prednisone and azithromycin was prescribed; however, her

59 events of grade 3 or worse in the docetaxel, prednisone and custirsen group (n=501) compared with the

60 e than have been reported for treatment with prednisone and deflazacort, and that vamorolone treatmen

61 for vamorolone than published incidences for prednisone and deflazacort.

62 Combined treatment with prednisone and either ciclosporin or methotrexate was mo

63 d Drug Administration-approved therapy) from prednisone and mitoxantrone and was predictive of overal

64 clophosphamide/methylprednisolone infusions, prednisone and mycophenolate.

65 Dosing of prednisone and safety were also assessed.

66 SG patients were subjected to treatment with prednisone and/or glucocorticoid-sparing agents.

67 ver from placebo to abiraterone acetate plus prednisone) and hypokalaemia (70 [12%] vs ten [2%] vs tw

68 lophosphamide, doxorubicin, vincristine, and prednisone) and R-FM (rituximab plus fludarabine and mit

69 lophosphamide, doxorubicin, vincristine, and prednisone) and the other half with R-ACVBP (rituximab,

70 lophosphamide, vincristine, doxorubicin, and prednisone) and the rituximab (R)-CHOP eras.

71 ituximab, cyclophosphamide, vincristine, and prednisone, and a clinical trial validation cohort compr

72 nisone, and lenalidomide (DPL) or docetaxel, prednisone, and a placebo (DP).

73 43%) of 501 patients treated with docetaxel, prednisone, and custirsen and 181 (36%) of 499 receiving

74 trial, of whom 510 were assigned docetaxel, prednisone, and custirsen and 512 were allocated docetax

75 igned 1:1 centrally to either the docetaxel, prednisone, and custirsen combination or docetaxel and p

76 ibutable to 23 (5%) deaths in the docetaxel, prednisone, and custirsen group and 24 (5%) deaths in th

77 Patients assigned docetaxel, prednisone, and custirsen received weekly doses of custi

78 .4 months [95% CI 20.9-24.8] with docetaxel, prednisone, and custirsen vs 22.0 months [19.5-24.0] wit

79 (2) intravenously every 3 weeks, 10 mg daily prednisone, and granulocyte colony-stimulating factor) v

80 059 patients with mCRPC receiving docetaxel, prednisone, and lenalidomide (DPL) or docetaxel, prednis

81 Melphalan, prednisone, and lenalidomide, followed by lenalidomide m

82 and treatment-related mortality, response to prednisone, and minimal residual disease (MRD) at end of

83 protocol included thymoglobulin, tacrolimus, prednisone, and mycophenolate mofetil.

84 trial, 526 patients treated with docetaxel, prednisone, and placebo in the MAINSAIL trial, 598 patie

85 doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab (DA-EPOCH-R) may obviate the n

86 L (target trough level (Ctrough, 3-8 ng/mL), prednisone, and tacrolimus (TCL) (target Ctrough, 2-5 ng

87 Glucocorticoid steroids such as prednisone are prescribed for chronic muscle conditions

88 Glucocorticoid steroids, like prednisone, are known to delay loss of ambulation in pat

89 support the use of abiraterone acetate plus prednisone as a standard of care in patients with high-r

90 partial response (PR) rates for sirolimus vs prednisone as initial treatment of patients with standar

91 s choice of enzalutamide or abiraterone plus prednisone as the control therapy (131 patients).

92 to receive enzalutamide or abiraterone plus prednisone as the control therapy, despite substantial c

93 e magnitude of systemic side effects as oral prednisone at a 5-mg daily dose.

94 ophosphamide, vincristine, procarbazine, and prednisone at baseline over ABVD was not observed.

95 Index (CDAI) of 150-450 depending on dose of prednisone at baseline, and no previous use of immunomod

96 All patients in both groups received oral prednisone at doses titrated up to 100 mg on alternate d

97 93 patients (14.3%) who received >= 10 mg of prednisone at the time of immunotherapy initiation had s

98 patients with NSCLC treated with >= 10 mg of prednisone at the time of immunotherapy initiation have

99 lophosphamide, doxorubicin, vincristine, and prednisone) at the British Columbia Cancer Agency.

100 PANTHER-IPF (Evaluating the Effectiveness of Prednisone, Azathioprine and N-Acetylcysteine in Patient

101 ic pulmonary fibrosis in a clinical trial of prednisone, azathioprine, and N-acetylcysteine underwent

102 In PANTHER-IPF, exposure to prednisone/azathioprine/N-acetylcysteine was associated

103 ophosphamide, vincristine, procarbazine, and prednisone (BEACOPP [68%]), followed by the combination

104 ophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) was comparable to that of patients

105 ophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc) and INRT (superiority design).

106 All patients received a mandatory prednisone burst followed by tapering of prednisone over

107 th patients in VISUAL-1 receiving an initial prednisone burst.

108 tion with cyclophosphamide, doxorubicin, and prednisone (BV-CHP) vs cyclophosphamide, doxorubicin, vi

109 s (block size 8) to receive cabazitaxel plus prednisone (cabazitaxel 25 mg/m(2) intravenously every 2

110 rm of ATRA + idarubicin + arsenic trioxide + prednisone), CALGB C9710 (single arm of ATRA + cytarabin

111 lophosphamide, doxorubicin, vincristine, and prednisone (CHOP) +/- rituximab were used.

112 lophosphamide, doxorubicin, vincristine, and prednisone (CHOP) by Coiffier and colleagues was the fir

113 lophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy as a standard in the mana

114 clophosphamide, adriamycin, vincristine, and prednisone (CHOP) chemotherapy.

115 lophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for the treatment of CD30-positive per

116 lophosphamide, doxorubicin, vincristine, and prednisone (CHOP), nowadays represent the standard first

117 lophosphamide, doxorubicin, vincristine, and prednisone [CHOP] or eight cycles of cyclophosphamide, v

118 zumab and cyclophosphamide, doxorubicin, and prednisone (CHP) in patients with previously untreated d

119 lophosphamide, doxorubicin, vincristine, and prednisone) clearly show the clinical value of the appro

120 y distress syndrome (odds ratio for 30 mg of prednisone compared with 5 mg 0.53; 95% CI, 0.32-0.86).

121 At 5 years, thymectomy plus prednisone continues to confer benefits in patients with

122 lophosphamide, doxorubicin, vincristine, and prednisone) could overcome these difficulties, but blood

123 tion with cyclophosphamide, vincristine, and prednisone (CVP) in patients with newly diagnosed advanc

124 cycles of cyclophosphamide, vincristine, and prednisone [CVP]), every 3 weeks during induction, then

125 with three cycles of doxorubicin/vincristine/prednisone/cyclophosphamide (AV-PC).

126 combination with bortezomib, melphalan, and prednisone (D-VMP) versus bortezomib, melphalan, and pre

127 rface area intravenously every 3 weeks, plus prednisone daily and granulocyte colony-stimulating fact

128 flammation in both eyes, no more than 7.5 mg prednisone daily and less than or equal to 2 drops of pr

129 nhibitor (either 1000 mg of abiraterone plus prednisone daily or 160 mg of enzalutamide daily).

130 the mitoxantrone data were compared with the prednisone data (41, 39, and 41 patients in the three mi

131 A(+)), 19 patients with eosinophilic asthma (prednisone dependent), and 13 healthy volunteers.

132 autoimmune event occurring in the airways of prednisone-dependent asthmatic patients with increased e

133 Median time to prednisone discontinuation was 35.8 months with predniso

134 ted means of the QMG score and alternate-day prednisone dose from month 0 to month 60.

135 Equation (GEE) model, each 10 mg increase in prednisone dose is associated with a 1.5- and 2.6-fold i

136 on of VKH upon CS withdrawal at a daily oral prednisone dose of 10 mg or more.

137 The cumulative median prednisone dose over the 52-week period was 1862 mg in e

138 eks and were taking a stable prednisolone or prednisone dose to receive 300 mg of mepolizumab or plac

139 .34 [5.08]; p=0.0007) and mean alternate-day prednisone doses (24 mg [SD 21] vs 48 mg [29]; p=0.0002)

140 However, daily prednisone dosing also correlated with increased muscle

141 at in murine models of LGMD 2B and 2C, daily prednisone dosing reduced muscle damage and fibroinflamm

142 hase III clinical trials with docetaxel plus prednisone (DP) or a DP-containing regimen.

143 ophosphamide, vincristine, procarbazine, and prednisone (eBEACOPP) for 6 cycles.

144 ophosphamide, vincristine, procarbazine, and prednisone (eBEACOPP) for six cycles.

145 prolide (EL) with or without abiraterone and prednisone (ELAP) before radical prostatectomy (RP) in m

146 e, and doxorubicin with cyclophosphamide and prednisone (EPOCH), were identified.

147 patients receiving oral corticosteroids, in prednisone equivalents, was 10 mg (interquartile range,

148 ituximab, cyclophosphamide, vincristine, and prednisone, event-free survival has improved and the ris

149 e and chronic graft-versus-host disease, and prednisone exposure.

150 lymphocytic leukemia and being treated with prednisone, fludarabine, cyclophosphamide, and rituximab

151 We found that prednisone, fluticasone, budesonide, and progesterone ea

152 cyclophosphamide, doxorubicin, vincristine, prednisone) followed by 3 cycles of ICE (ifosfamide, car

153 PFS or mOS in patients receiving >= 10 mg of prednisone for cancer-unrelated indications compared wit

154 compared with patients who received >= 10 mg prednisone for cancer-unrelated reasons and with patient

155 er only among patients who received >= 10 mg prednisone for palliative indications compared with pati

156 lophosphamide, doxorubicin, vincristine, and prednisone) for diffuse large B-cell lymphoma, which hav

157 lophosphamide, doxorubicin, vincristine, and prednisone) for DLBCL.

158 sing 476 patients treated with docetaxel and prednisone from the ASCENT2 trial, 526 patients treated

159 2013 plus cyclophosphamide, vincristine, and prednisone (GP2013-CVP) with rituximab-CVP (R-CVP) in pa

160 21 (81.0%) patients in the avacopan without prednisone group (difference from control 11.0%; two-sid

161 ) patients in the avacopan plus reduced-dose prednisone group (difference from control 16.4%; two-sid

162 atients each in the abiraterone acetate plus prednisone group (gastric ulcer perforation, sudden deat

163 antly longer in the abiraterone acetate plus prednisone group (median 53.3 months [95% CI 48.2-not re

164 igned to either the abiraterone acetate plus prednisone group (n=597) or placebo group (n=602).

165 [46%] of 597 in the abiraterone acetate plus prednisone group and 343 [57%] of 602 in the placebo gro

166 1%] patients in the abiraterone acetate plus prednisone group and none in the other groups).

167 At 5 years, patients in the thymectomy plus prednisone group had significantly lower time-weighted m

168 n (125 [21%] in the abiraterone acetate plus prednisone group vs 60 [10%] in the placebo group vs thr

169 ily orally and ADT (abiraterone acetate plus prednisone group) or matching placebos plus ADT (placebo

170 irsen group and n=318 in the cabazitaxel and prednisone group).

171 597 patients in the abiraterone acetate plus prednisone group, 151 (25%) of 602 in the placebo group,

172 14 (42%) of 33 patients in the prednisone group, and 12 (34%) of 35 in the thymectomy p

173 ) patients in the avacopan plus reduced-dose prednisone group, and 21 of 22 (96%) patients in the ava

174 nt related, versus 17 in the cabazitaxel and prednisone group, eight of which were deemed to be treat

175 p, and 12 (34%) of 35 in the thymectomy plus prednisone group, had at least one adverse event by mont

176 of 22 (96%) patients in the avacopan without prednisone group.

177 terior synechiae (aHR, 1.81); current use of prednisone >7.5 mg/day (aHR, 1.86); periocular corticost

178 ory EGPA receiving stable OGCs (prednisolone/prednisone, >=7.5-50 mg/d) for 4 or more weeks.

179 months with cabozantinib and 9.8 months with prednisone (hazard ratio, 0.90; 95% CI, 0.76 to 1.06; st

180 s 22.0 months [19.5-24.0] with docetaxel and prednisone; hazard ratio [HR] 0.93, 95% CI 0.79-1.10; p=

181 lophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy compared with DHITsig-nega

182 d not significantly improve OS compared with prednisone in heavily treated patients with mCRPC and pr

183 lophosphamide, doxorubicin, vincristine, and prednisone in the ECHELON-2 trial are practice changing

184 ine the efficacy of abiraterone acetate with prednisone in these high-risk patients with a suboptimal

185 ustirsen in combination with cabazitaxel and prednisone increases overall survival in patients with m

186 on (</=2 years or >2 years) after 8 weeks of prednisone induction therapy, or earlier if they had act

187 reduced following cGVHD therapies including prednisone, interleukin-2, or extracorporeal photophores

188 lophosphamide, doxorubicin, vincristine, and prednisone) into maintenance lenalidomide or placebo.

189 Prednisone is effective in both preventing and treating

190 isone-lenalidomide (MPR) or cyclophosphamide-prednisone-lenalidomide (CPR) or lenalidomide plus low-d

191 eligible to receive induction with melphalan-prednisone-lenalidomide (MPR) or cyclophosphamide-predni

192 The day 28 rate of CR/PR with prednisone <=0.25 mg/kg/day was significantly higher for

193 come was complete control of inflammation on prednisone <=10 mg/day, sustained for >=30 days.

194 ature eosinophils, sputum EoP numbers or the prednisone maintenance dose.

195 omatous Myasthenia Gravis Patients Receiving Prednisone (MGTX) showed that thymectomy combined with p

196 s were compared between study interventions (prednisone, mitoxantrone, and docetaxel) and off-treatme

197 and with patients receiving 0 to < 10 mg of prednisone (mPFS, 1.4 v 4.6 v 3.4 months, respectively;

198 s than patients who received 0 to < 10 mg of prednisone (mPFS, 2.0 v 3.4 months, respectively; P = .0

199 1:1), and 122 were AA1/2 (sirolimus, n = 58; prednisone, n = 64).

200 ituximab plus cyclophosphamide, vincristine, prednisone; n = 45, rituximab plus cyclophosphamide, dox

201 bitor), anakinra (IL-1 receptor antagonist), prednisone (NFkappaB translocation inhibitor), or ibupro

202 had an average daily dose of prednisolone or prednisone of 4.0 mg or less per day during weeks 48 thr

203 se oral cyclophosphamide to lenalidomide and prednisone offers a new therapeutic perspective for mult

204 custirsen in combination with docetaxel and prednisone on overall survival in patients with metastat

205 lestones by 2.1-2.7 years in comparison with prednisone or prednisolone (log-rank p<0.012).

206 aterone acetate 1000 mg once daily plus oral prednisone or prednisolone 5 mg twice daily during and a

207 rent treatment with abiraterone acetate plus prednisone or prednisolone and radium-223 in such patien

208 on of radium-223 to abiraterone acetate plus prednisone or prednisolone did not improve symptomatic s

209 Abiraterone acetate plus prednisone or prednisolone improves progression-free sur

210 trial, 598 patients treated with docetaxel, prednisone or prednisolone, and placebo in the VENICE tr

211 405) in addition to abiraterone acetate plus prednisone or prednisolone.

212 mly assigned (1:1) to either thymectomy plus prednisone or prednisone alone.

213 cyclophosphamide, doxorubicin, vincristine, prednisone or salvage immunochemotherapy.

214 hma maintained on high-dose corticosteroids, prednisone, or both.

215 ituximab plus cyclophosphamide, vincristine, prednisone: OR, 2.95; c-statistic, 0.75; P = .011; and r

216 lophosphamide, doxorubicin, vincristine, and prednisone: OR, 7.09; c-statistic, 0.88; P = .011).

217 etaxel 75 mg/m(2) intravenously with 5 mg of prednisone orally twice daily.

218 d the time-weighted average required dose of prednisone over a 3-year period.

219 ory prednisone burst followed by tapering of prednisone over the course of 15 weeks.

220 0.9% for dexamethasone and 80.8 +/- 0.9% for prednisone (P = .024).

221 ross over to receive abiraterone acetate and prednisone plus ADT treatment as per a protocol amendmen

222 significantly increased in patients assigned prednisone plus ciclosporin and prednisone plus methotre

223 ntly greater proportion of patients assigned prednisone plus ciclosporin had adverse events, affectin

224 domly assigned (n=317 in the cabazitaxel and prednisone plus custirsen group and n=318 in the cabazit

225 30 days of treatment in the cabazitaxel and prednisone plus custirsen group, seven of which were dee

226 d-sparing effect favoured the combination of prednisone plus methotrexate.

227 nts assigned prednisone plus ciclosporin and prednisone plus methotrexate.

228 in the prednisone alone group and 35 in the prednisone plus thymectomy group).

229 in the prednisone alone group and 26 in the prednisone plus thymectomy group.

230 rcaptopurine, vincristine, methotrexate, and prednisone (POMP), with four intensification courses (hi

231 These patients, classified as prednisone poor responders (PPR), have poorer outcome th

232 Ciprofloxacin AUC24 was 16.9 mg*h/L in the prednisone prophase versus 29.3 mg*h/L with concomitant

233 Conversely, intermittent dosing of prednisone, provided once weekly, enhanced muscle repair

234 lophosphamide, doxorubicin, vincristine, and prednisone (R-/G-CHOP) chemotherapy in B-cell NHL.

235 cin, cyclophosphamide, vindesine, bleomycin, prednisone (R-ACVBP) or rituximab, cyclophosphamide, dox

236 lophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and radiation therapy.

237 lophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and the impact of an end-of-treatmen

238 lophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as frontline therapy for diffuse lar

239 mab-cyclophosphamide-doxorubicin-vincristine-prednisone (R-CHOP) chemotherapy showed a rapid clearanc

240 lophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) could decrease rates of relapse and

241 lophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has become standard of care for pati

242 lophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in the RICOVER-60 trial.

243 lophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) on outcomes in previously untreated

244 lophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or intensive front-line therapy, and

245 lophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or R-CHOP-like therapy.

246 lophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)-14 (eight cycles) with rituximab plu

247 lophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).

248 lophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).

249 cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP14) induction and a positron emission

250 lophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP; or variant) across 7 multicenter ran

251 been reported after rapid discontinuation of prednisone (RDP) in kidney transplant recipients.

252 Cabazitaxel and prednisone remains the standard of care for patients wit

253 ith continuous low-dose cyclophosphamide and prednisone (REP) had remarkable activity in heavily pret

254 l symptoms, enzalutamide or abiraterone plus prednisone should be offered after discussion with patie

255 r relapsing vasculitis received placebo plus prednisone starting at 60 mg daily (control group), avac

256 tegy 2), or initial combination therapy with prednisone (strategy 3) or with infliximab (strategy 4),

257 the placebo group that underwent the 52-week prednisone taper (P<0.001 for the comparisons of either

258 the placebo group that underwent the 26-week prednisone taper and 18% of those in the placebo group t

259 prednisone taper, or placebo combined with a prednisone taper over a period of either 26 weeks or 52

260 or every other week, combined with a 26-week prednisone taper was superior to either 26-week or 52-we

261 or every other week, combined with a 26-week prednisone taper, or placebo combined with a prednisone

262 the placebo group that underwent the 26-week prednisone taper.

263 the placebo group that underwent the 52-week prednisone taper.

264 er was superior to either 26-week or 52-week prednisone tapering plus placebo with regard to sustaine

265 All patients underwent prednisone tapering, with patients in VISUAL-1 receiving

266 vir, intravitreal dexamethasone and systemic prednisone, the change in vision in OD improved from lig

267 ansplant recipients receiving tacrolimus and prednisone, the use of EVR was associated with higher in

268 lophosphamide, doxorubicin, vincristine, and prednisone therapy or the like.

269 s than patients who received 0 to < 10 mg of prednisone, this difference seems to be driven by a poor

270 dy, the addition of abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) led to

271 e the molecular differences and effects from prednisone treatment among IgG4-related disease with sal

272 eitis, or panuveitis despite having received prednisone treatment for 2 or more weeks.

273 Prednisone treatment led to increased neutrophil, but de

274 elated AEs among placebo patients during the prednisone treatment period in VISUAL-1 was statisticall

275 Prednisone treatment selectively modulates Treg, eosinop

276 the addition of custirsen to cabazitaxel and prednisone treatment.

277 2 participants and resolved with short-term prednisone treatment.

278 aterone (1000 mg orally once daily plus 5 mg prednisone twice daily) or enzalutamide (160 mg orally d

279 Acute kidney injury was not related to prednisone use (odds ratio [OR], 0.3; 95% confidence int

280 ts compared with baseline or CDAI >/=200, or prednisone use in the previous week).

281 C-reactive protein >/=5mg/L, CDAI >/=150, or prednisone use in the previous week; clinical management

282 EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubic

283 III study, compared dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin,

284 ne (D-VMP) versus bortezomib, melphalan, and prednisone (VMP) alone in patients with transplant-ineli

285 al report that bortezomib plus melphalan and prednisone (VMP) and lenalidomide plus low-dose dexameth

286 ion of custirsen to first-line docetaxel and prednisone was reasonably well tolerated, but overall su

287 (MGTX) showed that thymectomy combined with prednisone was superior to prednisone alone in improving

288 lone, tacrolimus, mycophenolate mofetil, and prednisone were commenced.

289 ted with immunotherapy who received >= 10 mg prednisone were compared with outcomes in patients who r

290 ansplant recipients receiving tacrolimus and prednisone were randomized for 3 different regimens: rab

291 clophosphamide, doxorubicin, vincristine and prednisone, where the majority of dogs achieve complete/

292 ient with active uveitis taking 60 mg/day of prednisone will experience, on average, an additional 10

293 nt with inactive uveitis taking 35 mg/day of prednisone will experience, on average, an additional 23

294 The combination of abiraterone acetate plus prednisone with ADT was associated with significantly lo

295 The patient was started on oral prednisone with rapid resolution of symptoms.

296 imab plus cyclophosphamide, vincristine, and prednisone) with R-CHOP (rituximab plus cyclophosphamide

297 cyclophosphamide, vindesine, bleomycin, and prednisone), with no significant impact on outcome.

298 lophosphamide, doxorubicin, vincristine, and prednisone), with the latter selected to permit comparis

299 lophosphamide, doxorubicin, vincristine, and prednisone, with (R-CHOP) or without (CHOP) rituximab is

300 lophosphamide, doxorubicin, vincristine, and prednisone, with or without melatonin.

301 us and randomly assigned to abiraterone plus prednisone without (arm A) or with veliparib (arm B).